
    
      Stereotactic ablation radiotherapy (SABR) was performed sequentially on the primary and
      secondary lesions. 50Gy/4F or 70Gy/10F were used according to the specific location of the
      tumor. Immunotherapy was started 2 weeks after the end of radiotherapy. Sintilimab : 200 mg
      intravenously, Q3W every cycle , given on the D1 of each cycle, and total of 4 cycles.
    
  